Stay updated on Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial
Sign up to get notified when there's something new on the Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial page.

Latest updates to the Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe ClinicalTrials.gov record for the rucaparib and pembrolizumab maintenance study is displayed, including its terminated status, study design, eligibility criteria, locations, and posted results information.SummaryDifference51%

- Check14 days agoChange DetectedThe site revision label in the footer changed from v3.7.2 to v3.8.0, while the 403 error page remained unchanged.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe displayed site revision changed from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now shows a 403 Forbidden error instead of the study details for NCT03559049, indicating access restrictions. As a result, users cannot view the study information on this page until access is restored.SummaryDifference19%

Stay in the know with updates to Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib Pembrolizumab Maintenance in Stage IV NSCLC Clinical Trial page.